Indefinite Delivery Contract SPE2DX16D2911
- Not listed
- The federal contract IDV award, SPE2DX15D1921, is a single-award Indefinite Delivery Contract (IDC) held by Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The contract, valued at up to $4,999,999.00, was awarded by the Defense Logistics Agency (DLA) Troop Support Medical and runs through December 31, 2025. Under this IDC, Amerisourcebergen Drug Corp provides a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The...
- The federal contract IDV award SPE2DX15D2004 is a single-award Indefinite Delivery Contract (IDC) issued by the Defense Logistics Agency (DLA) Troop Support Medical to the prime contractor Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The contract, valued at up to $4,999,999.00, runs through December 31, 2025 and aims to provide a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The IDC encompasses a broad spectrum...
- The federal contract IDV award SPE2DX16D1906 is an Indefinite Delivery Contract (IDC) held by Amerisourcebergen Drug Corp, a subsidiary of the parent company Cencora, Inc. This single-award IDC, valued at up to $999,999,999.00, was issued by the Defense Logistics Agency (DLA) Troop Support Medical and runs through December 31, 2025. It serves as the primary vehicle for Amerisourcebergen to deliver a comprehensive range of pharmaceutical products and medical supplies to support military...
- The federal contract IDV award, SPE2DX16D3903, is an Indefinite Delivery Contract (IDC) held by Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The contract, valued at up to $4,999,999.00, was awarded by the Defense Logistics Agency (DLA) Troop Support Medical to provide a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The contract encompasses critical medical commodities including specialty medications, brand-name...
- The federal contract IDV award SPE2DX15D1042 is a single-award Indefinite Delivery Contract (IDC) held by Amerisourcebergen Drug Corp, a subsidiary of the parent company Cencora, Inc. The $4,999,999.00 contract was awarded by the Defense Logistics Agency (DLA) Troop Support Medical on April 10, 2015, with a performance period through December 31, 2025. Under this IDC, Amerisourcebergen Drug Corp serves as the prime vendor responsible for delivering a comprehensive range of pharmaceutical...
- The federal contract IDV award SPE2DX15D6042 is a single-award Indefinite Delivery Contract (IDC) held by Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The contract, valued at up to $4,999,999.00, was awarded by the Defense Logistics Agency (DLA) Troop Support Medical and runs through December 31, 2025. Under this IDC, Amerisourcebergen Drug Corp provides a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The...
- The federal contract IDV award SPE2DX16D2902, a single-award Indefinite Delivery Contract (IDC) valued at up to $4,999,999.99, was issued by the Defense Logistics Agency (DLA) Troop Support Medical to the prime contractor Amerisourcebergen Drug Corp, a subsidiary of the parent company Cencora, Inc. The contract, which runs through December 31, 2025, aims to provide the DLA with a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally....
- The federal contract IDV award SPE2DX16D3923 is a single-award Indefinite Delivery Contract (IDC) held by Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The $4,999,999.00 contract was awarded by the Defense Logistics Agency (DLA) Troop Support Medical program on March 22, 2016, with a period of performance through November 23, 2023. Under this IDC, Amerisourcebergen Drug Corp provides a comprehensive range of pharmaceutical products and medical supplies to support military healthcare...
- The federal contract IDV award is a single-award Indefinite Delivery Contract (IDC) held by Amerisourcebergen Drug Corp, a subsidiary of the parent company Cencora, Inc. The contract, valued at up to $4,999,999.99, was awarded by the Defense Logistics Agency (DLA) Troop Support Medical and runs through December 31, 2025. Under this IDC, Amerisourcebergen Drug Corp is the prime contractor responsible for providing a comprehensive range of pharmaceutical products and medical supplies to support...
- The federal contract IDV award SPE2DX15D6043 is a single-award Indefinite Delivery Contract (IDC) held by Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The contract, valued at up to $4,999,999.00, was awarded by the Defense Logistics Agency (DLA) Troop Support Medical and runs through December 31, 2025. Under this IDC, Amerisourcebergen Drug Corp serves as the primary vendor for providing a comprehensive range of pharmaceutical products and medical supplies to support military...
The federal contract IDV award SPE2DX16D2911 is an Indefinite Delivery Contract (IDC) held by Amerisourcebergen Drug Corp, a subsidiary of the parent company Cencora, Inc. The single-award IDC, valued at up to $4,999,999.99, was issued by the Defense Logistics Agency (DLA) Troop Support Medical and runs through December 31, 2025. Under this IDC, Amerisourcebergen Drug Corp provides a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The contract encompasses critical medical commodities including specialty medications, brand-name and generic drugs, vaccines, syringes, vials, and test kits across multiple therapeutic domains such as cardiovascular health, diabetes management, mental health treatments, pain management, infectious disease prevention, and general medical care. The contract does not have any set-aside requirements, indicating open competition. In addition to the DLA IDC, Amerisourcebergen Drug Corp also holds a separate IDC with the Department of Justice Federal Bureau of Investigation, valued at up to $750,000 through May 2024, for similar medical products and prescription drugs.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $0 | 3/2/16 |